Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log out of your HL account

Provectus Biopharmaceuticals Inc (PVCT) USD0.001

Sell:$0.0625 Buy:$0.0625 Change: $0.0035 (5.30%)
Market closed |  Prices as at close on 17 October 2019 | Switch to live prices |
Sell:$0.0625
Buy:$0.0625
Change: $0.0035 (5.30%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Deal now
Market closed |  Prices as at close on 17 October 2019 | Switch to live prices |
Sell:$0.0625
Buy:$0.0625
Change: $0.0035 (5.30%)
Market closed |  Prices as at close on 17 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

Contact details

Address:
10025 Investment Dr Ste 250
KNOXVILLE
37932-2664
United States
Telephone:
+1 (865) 7694011
Website:
www.provectusbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PVCT
ISIN:
US74373P1084
Market cap:
$25.58 million
Shares in issue:
387.59 million
Sector:
Pharmaceuticals
Exchange:
OTC Bulletin Board
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Edward Pershing
    Chairman of the Board
  • Timothy Scott
    President
  • Dominic Rodrigues
    Vice Chairman of the Board
  • Heather Raines
    Chief Financial Officer
  • Bruce Horowitz
    Chief Operating Officer, Director
  • Eric Wachter
    Chief Technology Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.